Market capitalization | $35.98b |
Enterprise Value | $36.61b |
P/E (TTM) P/E ratio | 35.38 |
EV/FCF (TTM) EV/FCF | 28.13 |
EV/Sales (TTM) EV/Sales | 7.81 |
P/S ratio (TTM) P/S ratio | 7.68 |
P/B ratio (TTM) P/B ratio | 7.40 |
Dividend yield | 0.78% |
Last dividend (FY24) | $1.92 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
23 Analysts have issued a ResMed forecast:
23 Analysts have issued a ResMed forecast:
Jun '24 |
+/-
%
|
||
Revenue | 4,685 4,685 |
11%
11%
|
|
Gross Profit | 2,609 2,609 |
13%
13%
|
|
EBITDA | 1,600 1,600 |
19%
19%
|
EBIT (Operating Income) EBIT | 1,384 1,384 |
20%
20%
|
Net Profit | 1,021 1,021 |
14%
14%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Mick Farrell |
Employees | 9,980 |
Founded | 1989 |
Website | www.resmed.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.